CN102058632B - Application of medicinal composition to preparation of medicament for preventing and treating alcoholic liver damage and fatty liver and lowering blood fat - Google Patents
Application of medicinal composition to preparation of medicament for preventing and treating alcoholic liver damage and fatty liver and lowering blood fat Download PDFInfo
- Publication number
- CN102058632B CN102058632B CN2010106075380A CN201010607538A CN102058632B CN 102058632 B CN102058632 B CN 102058632B CN 2010106075380 A CN2010106075380 A CN 2010106075380A CN 201010607538 A CN201010607538 A CN 201010607538A CN 102058632 B CN102058632 B CN 102058632B
- Authority
- CN
- China
- Prior art keywords
- ilicis rotundae
- cortex ilicis
- fatty liver
- extract
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an ilicis routundae cortex medicinal composition for preventing and treating alcoholic liver damage, alcoholic fatty liver, non-alcoholic fatty liver and hyperlipidemia. The composition is extracted and refined from natural ilicis routundae cortex and is not chemically modified, and is characterized by comprising substances such as pedunculoside, syringin, rotundicacid and the like. The invention also discloses a preparation method of the ilicis routundae cortex composition and application to preparation of a medicament for preventing and treating the alcoholic liver damage, the alcoholic fatty liver and the non-alcoholic fatty liver and lowering blood fat.
Description
Technical field
The present invention relates to a kind of new method and medical usage of the pharmaceutical composition that from Cortex Ilicis Rotundae (Ilicis routundae cortex), extracts, a kind of specifically pharmaceutical composition with prevention and treatment alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and hyperlipidemia.Also relate to the pharmaceutical preparation of this medicine, the invention belongs to medical technical field.
Background technology
Fatty liver is not a kind of independently disease, is the liver fat degeneration that is caused by the multiple disease and the cause of disease.The modal cause of disease has obesity, alcoholism, is nutritional disorder, diabetes, drug intoxication, gestation, heredity etc. secondly.The liver fat degeneration can influence liver function, and part patient also possibly further develop becomes hepatitis, hepatic fibrosis and liver cirrhosis.The sickness rate of China's fatty liver has the trend that increases gradually.Though the name of disease of the fat-free liver of Chinese medicine belongs to " disease is long-pending " " hypochondriac pain " categories such as " jaundice " mostly according to its clinical manifestation.The traditional Chinese medical science thinks that mostly the fatty liver cause is surfeit delicious food savoury, obesity; Or insobriety, or experience the epidemic disease caused by damp-heat pathogen poison, or disorder of emotion; Or weakness due to chronic disease and food stagnation, the stagnation of QI, pestilential pathogen etc. all can cause primary disease, and its diseased region is liver, and is closely related with internal organs such as liver, gallbladder, spleen, stomach, kidneys; To its pathogenetic understanding; Numerous scholars all think the liver failing to maintain the normal flow of QI, dysfunction of the spleen in transportation, retention of damp-heat in the interior, the turbid pent-up of expectorant, stagnation of blood stasis and finally form damp-phlegm stasis of blood resistance knot mutually, numbness resistance liver venation and form fatty liver.
Alcoholic liver is because the hepar damnification property disease due to the long-term heavy drinking (being addicted to drink).Over past ten years, the expansion of Along with people's growth in the living standard and social circle, the consumption figure surge of global wine.Simultaneously, the generation of alcoholic liver also significantly increases.Because the incidence rate that causes alcoholic liver of drinking also is obvious ascendant trend, become the latent type killer who can not be ignored in China.In American-European countries, alcoholic cirrhosis accounts for the 50-90% of whole liver cirrhosis.Long-term alcoholic also influences lipid metabolism, can cause fatty liver, and ethanol can make hepatocellular degeneration, necrosis, proliferation of fibrous tissue and cause liver cirrhosis.
Mostly the medicine of treatment fatty liver and alcoholic liver injury is compound Chinese medicinal preparation at present; Therefore; Develop a clear and definite chemical component drugs thing that has with prevention and treatment alcoholic liver injury, fatty liver and hyperlipidemia safe and effective, that toxic and side effects is little, the patient is needed just.We belong to a kind of natural drug composition at the patent of invention, and chemical constituent is clear, and its purposes relates to the application to alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and blood fat reducing aspect.
Cortex Ilicis Rotundae (Ilicis routundae cortex) derives from the dry bark of holly plant Ilex rotunda Thunb. (Ilex rotunda Thunb.).Ilex rotunda Thunb. grows in deserted mountain sparse woods, hills or small stream limit, mainly is distributed in provinces and regions such as Guangdong, Guangxi, Fujian.Bitter in the mouth, cold in nature has effects such as heat-clearing and toxic substances removing, reducing swelling and alleviating pain, dampness removing, the expelling summer-heat that dispels the wind, and records in " south of the Five Ridges gather medicinal herbs record "; Claim that " bitter in the mouth, heat clearing away poison " is China's southern area traditional herbal medicine (Huang Wenjian, the application among the people of Cortex Ilicis Rotundae, Jiangxi Chinese medicine; 1996,2:147).The Cortex Ilicis Rotundae bark contains flavonoid glycoside, phenols, tannin, triterpene glycosides.Be usually used in flu, tonsillitis clinically, pharyngolaryngitis, acute gastroenteritis, dysentery, osteodynia etc.Utilizing the medicine of Cortex Ilicis Rotundae medical material for raw material production at present, mainly all is crude extract, and preparation technology is mainly with water extract-alcohol precipitation, and extract is dry, pulverize the method for directly being used as medicine.Bibliographical information syringoside have to galactosamine cause hepatotoxic protective action (foreign medical science Chinese medicine fascicle 2000, the 22nd the volume, the 6th phase, 346-347); Finding the patent (CN101342205) of Liu state firewood invention in the literature search, is to use the Cortex Ilicis Rotundae medical material, adds ethanol extraction; Filter, concentrate, after adding water and stirring; The leaching precipitate, the dry extract that gets, containing Peltatin glucoside and rotundicacid total amount in the 1g extract dry product is 0.50～0.80g; Wherein Peltatin glucoside and rotundicacid mass ratio are 12～1.5: 1, and the two content only accounts for 50～80% of total extract in this extract, and wherein major ingredients is a Peltatin glucoside; The effect of blood fat reducing is arranged, but do not contain syringoside in this extract, essential difference is arranged with our patent of invention.
We prove experimentation; The pharmaceutical composition of forming by Peltatin glucoside (Pedunculoside) 30-70%, syringoside (Syringin) 6-25%, rotundicacid (rotundic acid) 1-5%; Be from the naturally occurring Chinese crude drug Cortex Ilicis Rotundae of nature, to extract and get; Do not pass through any chemical modification; Effect with prevention and treatment alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and hyperlipidemia, the present invention other bibliographical informations relatively have very big progress and essential difference.
Before the present invention accomplishes; The pharmaceutical composition that does not also have bibliographical information to form by Peltatin glucoside, syringoside, rotundicacid; Report with prevention and treatment alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and hyperlipidaemic conditions does not find that this compositions is used to prevent and treat the clinicing aspect application of alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and hyperlipidemia yet.The compositions of also not finding simultaneously from other natural Chinese medicines, to extract of forming by Peltatin glucoside, syringoside, rotundicacid.
Summary of the invention
Goal of the invention provides a kind of Cortex Ilicis Rotundae compositions; Be used to prevent and treat the research and development of the medicine of diseases such as alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and hyperlipidemia; The present invention studies the effective ingredient of Chinese crude drug Cortex Ilicis Rotundae; Seek new effective site; Show that through further research the pharmaceutical composition of being made up of Peltatin glucoside, syringoside, rotundicacid has very strong pharmacological action to alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and hyperlipidemia etc.This natural pharmaceutical composition does not also find to have outstanding contribution in other medical materials.
Pharmaceutical composition of the present invention is to form by the Cortex Ilicis Rotundae medicinal material extract is refining, it is characterized in that, the Cortex Ilicis Rotundae pulverizing medicinal materials is become coarse powder, uses alcohol reflux, filters, and filtrate recycling ethanol filters, and gets extract I; Filtrating is not waved to nothing alcohol flavor, and through the macroporous resin column of having handled well, first water is to colourless, and the reuse ethanol elution concentrates ethanol liquid, gets extract II; Extract I and extract II are merged the dry Cortex Ilicis Rotundae pharmaceutical composition that gets.The Cortex Ilicis Rotundae compositions that the present invention extracts was with Cortex Ilicis Rotundae extract, the Cortex Ilicis Rotundae preparation of report had essential difference and significantly technological progress in the past.This natural pharmaceutical composition does not pass through any chemical modification simultaneously, has embodied the compound action of theory of Chinese medical science chemical constituent, has tangible novelty.
The invention has the beneficial effects as follows: filled up the effective site of preparation Cortex Ilicis Rotundae and comprise by saponins, plain type of phenylpropyl alcohol, pentacyclic triterpene acids composition blank as compositions; Simultaneously also expanded its range of application in field of medicaments, had very high using value the prevention and the treatment of alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and hyperlipidaemic conditions.Compositions is characterized in that; By weight: Peltatin glucoside 30-70%, syringoside 6-25%, rotundicacid 1-5%, this natural pharmaceutical formulation has clear and definite pharmacological action; In other Chinese crude drugs, also do not find to have very high value of exploiting and utilizing.
Another object of the present invention is that the pharmaceutical preparation of Cortex Ilicis Rotundae pharmaceutical composition is provided.Main drug form is tablet, capsule, pill, granule, suspensoid, drop pill, any in the injection.
Described Cortex Ilicis Rotundae preparation of pharmaceutical compositions method of the present invention is following:
The Cortex Ilicis Rotundae pulverizing medicinal materials is become coarse powder, doubly measures alcohol reflux 1-3 time of the 50-95% of medical material weight with 5-10, each 1-3 hour, filter, filtrate recycling ethanol filters, extract I; Filtrating is not waved to nothing alcohol flavor, and through the macroporous resin column of having handled well, first water is to colourless, and reuse 30-80% ethanol elution concentrates ethanol liquid, gets extract II; Extract I and extract II are merged the dry Cortex Ilicis Rotundae pharmaceutical composition that gets.
Method for distilling of the present invention has with short production cycle, workable, does not use inflammable and explosive chemical reagent, safety, and cost is low, can satisfy big need of industrial production.In view of the present invention has clear and definite pharmacologically active, the Cortex Ilicis Rotundae compositions of technology gained of the present invention can prepare in industrialization, has broad application prospects.
Peltatin glucoside, syringoside, rotundicacid high-efficient liquid phase chromatogram process measuring method:
With the octadecylsilane chemically bonded silica is filler; With acetonitrile-0.05% phosphate aqueous solution is mobile phase; Concrete ratio sees the following form, and the detection wavelength is 210nm.Number of theoretical plate calculates by syringoside and is not less than 3000.
The preparation precision of reference substance solution takes by weighing syringoside, Peltatin glucoside, rotundicacid reference substance, puts in the volumetric flask, processes every ml with dissolve with methanol and contains syringoside 0.05mg, Peltatin glucoside 0.15mg, rotundicacid 0.008mg mixed solution.
Compositions 20mg is got in the preparation of need testing solution, and accurate the title decides, and puts in the 50ml measuring bottle, adds methanol 40ml, and ultrasonic 30min is placed to room temperature, and methanol constant volume shakes up to scale, as need testing solution.
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of assay method inject chromatograph of liquid, measure, and promptly get.
The effect that Cortex Ilicis Rotundae pharmaceutical composition (syringoside accounts for 21.8%, Peltatin glucoside accounts for 57.6%, rotundicacid account for 3.6%) has prevention and treatment alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and hyperlipidemia; These pharmacological actions are confirmed through following pharmacodynamics test example.
1, the Cortex Ilicis Rotundae compositions is to the protective effect of alcoholic liver injury
50 of mices are divided into 5 groups at random, i.e. basic, normal, high three dose groups, ethanol model group and blank group of Cortex Ilicis Rotundae compositions.The Cortex Ilicis Rotundae composition component does not press Cortex Ilicis Rotundae compositions 50,100 and 200mg/kg irritates the stomach mice, and 1 time/d, be total to 14d, ethanol model group and blank control group matched group are irritated stomach equal-volume distilled water respectively, 1 time/d, are total to 14d.Fasting is 12 hours after the last administration, except that the blank group is still irritated stomach equivalent distilled water, and other 4 treated animals (basic, normal, high three dose groups of Cortex Ilicis Rotundae compositions; The ethanol model group) irritates stomach 50% ethanol 12mL/kg respectively; Vena ophthalmica is got blood behind the 6h, measures alanine aminotransferase (ALT) and aspartate amino transferase (AST) content in the serum, gets mouse liver and weighs; Measure liver device index; Get lobus dexter and measure (SOD) of superoxide dismutase, glutathione peroxidase (GSH-PX) activity, malonaldehyde (MDA) content.
Table 1 Cortex Ilicis Rotundae compositions is to the influence
of alcohol damaged mice serum ALT, AST and liver coefficient
Compare with the blank group: * P＜0.05, * * P＜0.01, * * * P＜0.001; The ethanol group is Δ p＜0.05 relatively, Δ Δ p＜0.01.
Can know from table 1, irritate stomach ethanol the Mouse Liver index is significantly increased, irritate stomach Cortex Ilicis Rotundae compositions alcohol damaged Mouse Liver index is significantly reduced.Irritate stomach ethanol mice serum ALT, AST are significantly increased, irritate stomach Cortex Ilicis Rotundae compositions alcohol damaged mice serum ALT, AST are significantly reduced.
Table 2 Cortex Ilicis Rotundae compositions is to the influence
of alcohol damaged mouse liver MDA, GSH-PX, SOD
Compare with the blank group: * P＜0.05, * * P＜0.01, * * * P＜0.001; The ethanol group is Δ p＜0.05 relatively, Δ Δ p＜0.01.
The result shows from table 2, and ethanol can cause that mouse liver MDA content significantly raises, causes GSH-PX enzyme, the active significantly reduction of SOD, and the Cortex Ilicis Rotundae compositions can significantly reduce MDA content, the GSH-PX enzyme that can significantly raise, SOD activity.
2, Cortex Ilicis Rotundae compositions fatty liver that hyperlipidemia and hyperlipidemia are caused improves function
Get 60 of male rats, be divided into 6 groups at random, except that the blank group, all the other are respectively organized and give high lipid food every day: 2% cholesterol, 10% Adeps Sus domestica, 0.5% sodium cholate, 0.2% propylthiouracil, 87% normal feedstuff.Except that the blank group was freely drunk water, the hyperlipidemia model group gave the equivalent normal saline, and all the other are respectively organized per os and irritate stomach, divide into groups according to table 1 every day 1 time, and administration, in 10 weeks of successive administration, fasting 12h can't help water after the last medication, the sacrificed by decapitation all animals.Broken end is got blood, surveys T-CHOL (TC), triglyceride (TG) in the blood, and high density lipoprotein (HDL-C), low-density protein (LDL-C) are measured the result and seen table 3; Get right lobe of liver 1g, process 10% homogenate under 4 ℃, 3000rpm 10min gets supernatant, measures the content of TC and TG respectively, measures the result and sees table 4; Get fresh liver tissue and process 1% LH, press the test kit operating instruction and measure SOD, GSH, VitE, adopt the thiobarbituricacid method to measure the content of hepatic tissue MDA, measure the result and see table 5 with normal saline.
Table 3 Cortex Ilicis Rotundae compositions influences result
to the hyperlipidemia rats blood lipids index
Compare * P＜0.05 with model control group; * P＜0.01; Compare Δ P＜0.05 with the blank group; Δ Δ P＜0.01;
The result shows; Model control group serum TC, TG, LDL-C value obviously raise; HDL-C descends; Can obviously reduce serum TC, TG content with model control group comparison Cortex Ilicis Rotundae compositions, significantly reduce serum low-density LP cholesterol (LDL-C) content, the content of serum high-density LP cholesterol (HDL-C) that significantly raise.
Table 4 Cortex Ilicis Rotundae compositions is to the influence
of TC, TG in the rats'liver
Compare with the blank group: * P＜0.05, * * P＜0.01; Model group is Δ p＜0.05 relatively, Δ Δ p＜0.01.
Can know that from table 4 model control group is compared with the blank group, TC, TG content significantly raise.Compare with model control group, the high, medium and low dose groups TC content of Cortex Ilicis Rotundae compositions all has significance to reduce, and Cortex Ilicis Rotundae combination object height, middle dose groups TG content also have significance to reduce.
Table 5 Cortex Ilicis Rotundae compositions is to the influence
of liver tissues of rats SOD, MDA, GSH, VitE content
Compare with the blank group: * P＜0.05, * * P＜0.01, * * * P＜0.001; Model group is Δ p＜0.05 relatively, Δ Δ p＜0.01, Δ Δ Δ p＜0.001.
Can know that from table 5 model control group and blank group compare, the decline of the active significance of SOD, MDA content obviously increases.Each group of medication is compared with model control group, and the SOD activity obviously increases, and MDA content obviously reduces, and returns to the level of approximate normal control group basically.Model group and normal control group comparison GSH and VitE content obviously reduce, and Cortex Ilicis Rotundae medication group can obviously improve the content of GSH and VitE.
3, Cortex Ilicis Rotundae compositions fatty liver that ethanol is caused improves function
120 of test rats are divided into the normal control group at random; The fatty liver model group; Positive control drug DONGBAO GANTAI 600mg/kg dosage group: the Cortex Ilicis Rotundae compositions is established 100mg/kg, 50mg/kg and three dosage groups of 25mg/kg.Totally 6 groups, 20 every group.Except that the normal control group, all the other are respectively organized rat 8:30 in morning every day filling stomach and give (56% ethanol+0.5mL fish oil) 1 time, and ethanol dosage begins to be 7g/kg, increases progressively 0.2g/kg subsequently weekly, continuous 4 weeks.Rats in normal control group is irritated stomach and is given isocaloric 56% glucose+0.5mL fish oil.Receive the reagent thing to be mixed with suspension with distilled water, 1:00 filling in afternoon every day stomach gives 1 time, and normal control group and model control group rat oral gavage give the distilled water of equivalent, irritate the long-pending 10ml/kg/d of being of body of stomach.The rat drinking-water of freely ingesting is weighed in weekly 1 time in the process of the test, with the adjustment dosage.The dead animal in end around administration the.Collection of specimens and observation index; Result of the test is added and subtracted standard deviation
expression with mean, t check between statistical procedures method employing group.Experimental result is seen table 6 and table 7.
Table 6 Cortex Ilicis Rotundae compositions is to alcoholic fatty liver rat blood serum ALT, AST and the active influence of LDH
Compare with the normal control group: * P＜0.05, * * P＜0.01, * * * P＜0.001; Model group is Δ p＜0.05 relatively, Δ Δ p＜0.01, Δ Δ Δ p＜0.001.
Cortex Ilicis Rotundae combination object height and middle administration treated animal Serum ALT and AST activity very significantly are lower than model group; This result of the test shows; Test sample Cortex Ilicis Rotundae compositions can obviously reduce the unusual ALT that raises, the activity of AST in the alcoholic fatty liver rat blood serum, explains that the Cortex Ilicis Rotundae compositions has good protective action to hepatocyte.Cortex Ilicis Rotundae combination object height and middle administration group have tangible reduction effect to the unusual rising of alcoholic fatty liver animal serum LDH level, and this result of the test shows, the Cortex Ilicis Rotundae compositions has good protective effect to fatty liver due to the ethanol.
Table 7 is rescued the heart and is answered the influence
of compositions to alcoholic fatty liver Serum TC, TG and MDA content and hepatic tissue TG content
Compare with the normal control group: * P＜0.05, * * P＜0.01, * * * P＜0.001; Model group is Δ p＜0.05 relatively, Δ Δ p＜0.01.
After giving Cortex Ilicis Rotundae compositions 100mg/kg, 50mg/kg and three different dosing dosage of 25mg/kg respectively and carrying out Drug therapy, wherein, MDA content is starkly lower than model group (for P＜0.01) in the Cortex Ilicis Rotundae compositions 100mg/kg administration treated animal serum.Show that the Cortex Ilicis Rotundae compositions can reduce fatty liver animal pattern Content of MDA, hepatocellular lipid peroxidation when suppressing fatty liver, thereby the effect that performance protection hepatocyte avoids damaging.Cortex Ilicis Rotundae combination object height with in two administration treated animal serum TC, TG content and hepatic tissue TG content significantly be lower than model control group (being respectively P＜0.01 or P＜0.05).Show that the Cortex Ilicis Rotundae compositions can reduce the rising of fatty liver rat fat content and liver lipid content due to the ethanol, has the effect that liver fat is piled up that suppresses.
Can know that from above pharmacodynamic experiment the Cortex Ilicis Rotundae compositions has the effect of prevention and treatment alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and hyperlipidemia, and takes for a long time and be free from side effects.
The present invention executes example through following experiment to be achieved (confirmation), but does not mean that this present invention just is limited to this, and the practical implementation method is following.
Instance 1
2kg is ground into coarse powder with the Cortex Ilicis Rotundae medical material, with 70% alcohol reflux of 8 times of amount medical material weight 3 times, and each 2 hours, filter, merging filtrate reclaims ethanol, to 2500ml, filters, and gets filter cake and gets extract I; Filtrating is not waved to there not being pure flavor, and through the D101 macroporous resin column of having handled well, first water is washed till colourless, and reuse 50% ethanol elution 4BV collects ethanol elution, reclaims ethanol, concentrates, and gets extract II; Extract I and extract II are merged, and drying gets Cortex Ilicis Rotundae pharmaceutical composition 158.6g.Utilize high effective liquid chromatography for measuring, calculate, syringoside accounts for 23.8%, Peltatin glucoside accounts for 59.1%, rotundicacid accounts for 2.9%.
Instance 2
2kg is ground into coarse powder with the Cortex Ilicis Rotundae medical material, with 50% alcohol reflux of 6 times of amount medical material weight 3 times, and each 3 hours, filter, merging filtrate reclaims ethanol, to 2500ml, filters, and gets filter cake and gets extract I; Filtrating is not waved to there not being pure flavor, and through the D101 macroporous resin column of having handled well, first water is washed till colourless, and reuse 60% ethanol elution 4BV collects ethanol elution, reclaims ethanol, concentrates, and gets extract II; Extract I and extract II are merged, and drying gets Cortex Ilicis Rotundae pharmaceutical composition 168.4g.Utilize high effective liquid chromatography for measuring, calculate, syringoside accounts for 19.7%, Peltatin glucoside accounts for 55.3%, rotundicacid accounts for 2.2%.
Instance 3
2kg is ground into coarse powder with the Cortex Ilicis Rotundae medical material, with 80% alcohol reflux of 8 times of amount medical material weight 2 times, and each 3 hours, filter, merging filtrate reclaims ethanol, to 2500ml, filters, and gets filter cake and gets extract I; Filtrating is not waved to there not being pure flavor, and through the AB-8 macroporous resin column of having handled well, first water is washed till colourless, and reuse 40% ethanol elution 4BV collects ethanol elution, reclaims ethanol, concentrates, and gets extract II; Extract I and extract II are merged, and drying gets Cortex Ilicis Rotundae pharmaceutical composition 148.6g.Utilize high effective liquid chromatography for measuring, calculate, syringoside accounts for 23.4%, Peltatin glucoside accounts for 60.1%, rotundicacid accounts for 3.4%.
Instance 4
2kg is ground into coarse powder with the Cortex Ilicis Rotundae medical material, with 50% alcohol reflux of 8 times of amount medical material weight 3 times, and each 2 hours, filter, merging filtrate reclaims ethanol, to 2500ml, filters, and gets filter cake and gets extract I; Filtrating is not waved to there not being pure flavor, and through the AB-8 macroporous resin column of having handled well, first water is washed till colourless, and reuse 35% ethanol elution 4BV collects ethanol elution, reclaims ethanol, concentrates, and gets extract II; Extract I and extract II are merged, and drying gets Cortex Ilicis Rotundae pharmaceutical composition 141.6g.Utilize high effective liquid chromatography for measuring, calculate, syringoside accounts for 23.9%, Peltatin glucoside accounts for 62.1%, rotundicacid accounts for 3.1%.Instance 5, (capsule)
Cortex Ilicis Rotundae pharmaceutical composition 100g, medical starch is an amount of, and mix homogeneously is granulated, drying, granulate, the capsule of packing into No. 1 is processed 1000, promptly gets.Each 1, every day 2 times.
Embodiment 6, (tablet)
Cortex Ilicis Rotundae pharmaceutical composition 100g, medical starch is an amount of, and dextrin is an amount of, and mix homogeneously is granulated, drying, granulate, drying, the adding lubricant is an amount of, and tabletting is processed 1000, promptly gets.Each 1, every day 2 times.
Embodiment 7, (drop pill)
Take by weighing the 15g Macrogol 4000, the 15g polyethylene glycol 6000 melts in water-bath; Cortex Ilicis Rotundae pharmaceutical composition 10g stirs, in the impouring insulating tube; Regulate thermostat, medicinal liquid is splashed in the liquid paraffin that cooled off, after dripping off under 8090 ℃; With blotting liquid paraffin on the pill impouring filter paper, process 1000, promptly get.Each 10, every day 2 times.
Embodiment 8, (granule)
Cortex Ilicis Rotundae pharmaceutical composition 100g, dextrin 400g, lactose 500g, mix homogeneously is used an amount of alcohol granulation, and drying, granulate, packing are processed 1000 bags, promptly get.Each 1 bag, every day 2 times.
Claims (4)
1. preparation of drug combination method of being extracted by Cortex Ilicis Rotundae is characterized in that: the Cortex Ilicis Rotundae pulverizing medicinal materials is become coarse powder, doubly measure alcohol reflux 1-3 time of the 50-95% of medical material weight with 5-10; Each 1-3 hour; Filter, filtrate recycling ethanol, extremely every 1ml contains the 0.8g medical material; Filter, get filter cake and get extract I; Filtrating is not waved to nothing alcohol flavor, and through D101 type or the AB-8 type macroporous resin column handled well, first water is washed till colourless, and reuse 30-80% ethanol elution is collected ethanol elution, concentrates, and gets extract II; Extract I and extract II are merged the dry Cortex Ilicis Rotundae pharmaceutical composition that gets.
2. Cortex Ilicis Rotundae pharmaceutical composition according to claim 1 is characterized in that: mainly be made up of Peltatin glucoside, syringoside and rotundicacid.
3. Cortex Ilicis Rotundae pharmaceutical composition according to claim 3, it is characterized in that by weight percentage: Peltatin glucoside accounts for 30-75%, and syringoside accounts for 6-25%, and rotundicacid accounts for 1-5%.
4. Cortex Ilicis Rotundae pharmaceutical composition according to claim 1, the application in the medicine of preparation alcoholic liver injury, alcoholic fatty liver, non-alcoholic fatty liver disease and blood fat reducing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106075380A CN102058632B (en) | 2010-12-28 | 2010-12-28 | Application of medicinal composition to preparation of medicament for preventing and treating alcoholic liver damage and fatty liver and lowering blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106075380A CN102058632B (en) | 2010-12-28 | 2010-12-28 | Application of medicinal composition to preparation of medicament for preventing and treating alcoholic liver damage and fatty liver and lowering blood fat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102058632A CN102058632A (en) | 2011-05-18 |
| CN102058632B true CN102058632B (en) | 2012-05-30 |
Family
ID=43994257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010106075380A Active CN102058632B (en) | 2010-12-28 | 2010-12-28 | Application of medicinal composition to preparation of medicament for preventing and treating alcoholic liver damage and fatty liver and lowering blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058632B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579517B (en) * | 2012-03-08 | 2014-03-19 | 吉林省中医药科学院 | Medicament composition for preventing prostatic diseases |
| CN102552297B (en) * | 2012-03-08 | 2013-09-18 | 吉林省中医药科学院 | Application of medicinal composition in preparation of alpha-glucuroide inhibitor medicines |
| CN102643322B (en) * | 2012-03-29 | 2014-03-19 | 中国中医科学院中药研究所 | Method for simultaneously preparing pedunculoside and syringin |
| CN103007081B (en) * | 2012-11-27 | 2013-12-04 | 鞠法红 | Traditional Chinese medicine composition for curing non-alcoholic fatty liver disease |
| CN103351419B (en) * | 2013-07-09 | 2015-10-07 | 陕西中药研究所 | Two-step approach prepares the method for pedunculoside and Syringin simultaneously |
| CN104510761A (en) * | 2014-02-18 | 2015-04-15 | 广西中医药大学附属瑞康医院 | Ovateleaf Holly Bark extract product having hepatic injury prevention effect, and application thereof |
| CN107281188A (en) * | 2017-06-01 | 2017-10-24 | 中山大学 | Purposes of the rotundic acid in anti-hepatic-B virus medicine is prepared |
| CN112480201A (en) * | 2019-09-12 | 2021-03-12 | 广州奈米微晶生物科技有限公司 | Preparation method of rotundic acid and application of rotundic acid in preparation of drug for treating non-alcoholic steatohepatitis |
| CN117797158A (en) * | 2024-02-18 | 2024-04-02 | 苏州卫生职业技术学院 | Application of ilexoside as active ingredient in preparation of anti-liver cancer drugs |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342205A (en) * | 2008-09-01 | 2009-01-14 | 刘国樵 | Traditional Chinese medicine preparation for decreasing blood fat |
| CN101849950A (en) * | 2010-06-22 | 2010-10-06 | 赵全成 | Application of rotundic acid in preparing blood lipid regulating medicines |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101099753A (en) * | 2006-07-07 | 2008-01-09 | 李超生 | Preparation method and application for general saponin of cortex ilecis rotundae |
-
2010
- 2010-12-28 CN CN2010106075380A patent/CN102058632B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342205A (en) * | 2008-09-01 | 2009-01-14 | 刘国樵 | Traditional Chinese medicine preparation for decreasing blood fat |
| CN101849950A (en) * | 2010-06-22 | 2010-10-06 | 赵全成 | Application of rotundic acid in preparing blood lipid regulating medicines |
Non-Patent Citations (1)
| Title |
|---|
| 陆继敏等.瑶医药治疗慢性乙型病毒性肝炎的临床研究.《河北中医》.2006,(第04期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102058632A (en) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102058632B (en) | Application of medicinal composition to preparation of medicament for preventing and treating alcoholic liver damage and fatty liver and lowering blood fat | |
| CN100594928C (en) | Curcuma extract and its prepn process, medicine composition and use | |
| CN101721488B (en) | Pharmaceutical composition for treating liver diseases and prepration method thereof | |
| CN103372051B (en) | Red rice and kudzuvine root medicinal composition for regulating blood fat and preparation method of the composition | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN1985927B (en) | Medicine composition for treating hepatic disease mainly | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN105708891A (en) | Drug composition for controlling and treating fatty liver of human body and application thereof | |
| CN102697781A (en) | Application of trigonelline in preparation of medicament for preventing and treating diabetes and complication thereof | |
| CN101829291B (en) | Traditional Chinese medicine preparation for treating rheumatism and preparation method thereof | |
| CN1939427B (en) | Prickly polygonum extract, its preparation, medicinal composition and use | |
| CN100558343C (en) | Chinese medicine preparation of the liver soothing and the spleen invigorating and preparation method thereof | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN105535533A (en) | Traditional Chinese medicine composition for treatinggastritis | |
| CN115006494A (en) | Inula flower composite anti-alcohol composition with pulse-displaying function, anti-alcohol and liver-protecting preparation and application thereof | |
| CN103372040B (en) | Monas cuspurpureus Went Rhizoma Chuanxiong drug regimen of a kind of adjusting blood lipid and preparation method thereof | |
| CN103877323B (en) | Medicinal composition for treating non-alcoholic fatty liver disease | |
| CN102641352A (en) | Sibiraea effective-part extract, preparation method and use thereof | |
| CN102579869A (en) | Preparation method of traditional Tibetan medicine composition for treating liver diseases | |
| CN101642541B (en) | Composition with hepatoprotective effect, preparation method and application thereof | |
| CN101112432A (en) | Fatty liver treating Chinese medicine and method for preparing the same | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
| CN104771463A (en) | Novel application of prunus padus extract in preparing alcoholic liver injury protection medicines and health products | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN104547026A (en) | Preparation method and application of salvia miltiorrhiza leave and panax pseudo-ginseng extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOP Free format text: FORMER OWNER: ZHAO QUANCHENG Effective date: 20120326 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20120326 Address after: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin Applicant after: Jilin xiuzheng pharmaceutical new medicine development Co., Ltd. Address before: 130012 Changchun high tech Zone, Jilin pioneering Street No. 155 Applicant before: Zhao Quancheng |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |